“San Antonio Breast Cancer Symposium Highlights.” by Dr. Julie Gralow, #BCSM.
The San Antonio Breast Cancer Symposium is the largest scientific meeting devoted to breast cancer, attracting national and international attention. It is attended by clinicians, researchers and advocates. “The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.”
Dr. Julie Gralow is a Breast Cancer and Global Oncology Specialist at the University of Washington and Seattle Cancer Care Alliance, and is also regular participant in the #BCSM tweet chats, attended the conference. Here are some of the studies she felt were most relevant to the breast cancer community, with her interpretation of the results.
- S1-04 The APT Study: Combining paclitaxel (Taxol) and trastuzumab (Herceptin) as adjuvant treatment for small, lymph node-negative, HER2+ breast cancer [Article link: http://www.ascopost.com/ViewNews.aspx?nid=10846]
- S3-03 The HOPE (HOrmone and Physical Exercise) trial: A randomized trial of exercise versus usual care in women experiencing arthralgias (joint aches) associated with aromatase inhibitors[Article link: http://ecancer.org/news/4905-sabcs-2013–exercise-improves-drug-associated-joint-pain-in-breast-cancer-survivors.php]
- S4-07 The affect of bisphosphonates on recurrence and death in early stage breast cancer: A meta-analysis from randomized trials[Article links: http://www.ascopost.com/ViewNews.aspx?nid=10847; http://www.medpagetoday.com/MeetingCoverage/SABCS/43435]
- Platinum agents in triple negative breast cancer: promising data in the preoperative therapy setting
- S5-01 CALGB C40603: Addition of carboplitin and/or bevacizumab (Avastin) to preoperative weekly paclitaxel (Taxol) followed by dose dense AC in triple negative breast cancer
- S5-02 I-SPY2 Trial: Veliparib (a PARP inhibitor) and carboplatin plus standard preoperative therapy for high risk breast cancer
- [Article links: http://www.ascopost.com/ViewNews.aspx?nid=10849; http://www.onclive.com/conference-coverage/sabcs-2013/Novel-Trial-Design-Shows-Early-Value-for-VeliparibCarboplatin-in-TNBC]
